ly2623091
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01237899)
Timeline
Indications
Mechanism of action
- Mineralocorticoid receptorANTAGONIST
NR3C2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](CN1CCOCC1)n1/c(=N\C(N)=O)[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc21- Mol. weight
- 527.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4088896 ↗
- ChEMBLCHEMBL3545275 ↗
Also known as
- ly2623091
- ly2623091
- ly2623091
- ly-2623091
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02300259 | Phase 1 | Nov 1, 2014 | Eli Lilly |
| NCT02242981 | Phase 1 | Sep 1, 2014 | Eli Lilly |
| NCT02194465 | Phase 2 | Aug 1, 2014 | Eli Lilly |
| NCT01427972 | Phase 2 | Sep 1, 2011 | Eli Lilly |
| NCT01237899 | Phase 1 | Oct 1, 2010 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 2 | 2010 |
1 organizations
Page 1 / 1